Patents by Inventor Lyle M. Bowman
Lyle M. Bowman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11154560Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.Type: GrantFiled: January 2, 2019Date of Patent: October 26, 2021Assignee: SUN PHARMA GLOBAL FZEInventors: Lyle M Bowman, Kamran Hosseini
-
Publication number: 20210205330Abstract: A method of treating non-infectious, inflammatory blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat the non-infectious, inflammatory blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.Type: ApplicationFiled: March 19, 2021Publication date: July 8, 2021Applicant: SUN PHARMA GLOBAL FZEInventors: Lyle M BOWMAN, Kamran HOSSEINI
-
Patent number: 10980818Abstract: A method of treating non-infectious, inflammatory blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat the non-infectious, inflammatory blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.Type: GrantFiled: December 31, 2018Date of Patent: April 20, 2021Assignee: SUN PHARMA GLOBAL FZEInventors: Lyle M Bowman, Kamran Hosseini
-
Publication number: 20200183808Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.Type: ApplicationFiled: January 2, 2019Publication date: June 11, 2020Applicant: SUN PHARMA GLOBAL FZEInventors: Lyle M. BOWMAN, Kamran HOSSEINI
-
Publication number: 20190332516Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.Type: ApplicationFiled: January 2, 2019Publication date: October 31, 2019Applicant: SUN PHARMA GLOBAL FZEInventors: Lyle M. BOWMAN, Kamran HOSSEINI
-
Publication number: 20190298738Abstract: A method of treating non-infectious, inflammatory blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat the non-infectious, inflammatory blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.Type: ApplicationFiled: December 31, 2018Publication date: October 3, 2019Applicant: SUN PHARMA GLOBAL FZEInventors: Lyle M. BOWMAN, Kamran Hosseini
-
Patent number: 9789080Abstract: Ophthalmic formulations including mycophenolic acid or salt thereof in an aqueous medium having a reduced level of dissolved oxygen and processes for making such formulations and using such formulations are disclosed.Type: GrantFiled: September 4, 2015Date of Patent: October 17, 2017Assignees: Insite Vision IncorporatedInventors: Sui Yuen Eddie Hou, Lyle M. Bowman, Tang Nguyen, Gholam Peyman
-
Publication number: 20170128481Abstract: Methods of treating a subject suffering from an ocular infection and/or ocular inflammation are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least two active agents in an ophthalmically acceptable vehicle that can provide a sustained release of the at least two active agents. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.Type: ApplicationFiled: July 9, 2015Publication date: May 11, 2017Inventors: Kamran HOSSEINI, Lyle M. BOWMAN
-
Publication number: 20170065552Abstract: Ophthalmic formulations including mycophenolic acid or salt thereof in an aqueous medium having a reduced level of dissolved oxygen and processes for making such formulations and using such formulations are disclosed.Type: ApplicationFiled: September 4, 2015Publication date: March 9, 2017Inventors: Sui Yuen Eddie HOU, Lyle M. BOWMAN, Tang NGUYEN, Gholam PEYMAN
-
Publication number: 20170007635Abstract: Methods of treating a subject suffering from an ocular infection and/or ocular inflammation are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least two active agents in an ophthalmically acceptable vehicle that can provide a sustained release of the at least two active agents. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.Type: ApplicationFiled: July 9, 2015Publication date: January 12, 2017Inventors: Kamran HOSSEINI, Lyle M. BOWMAN
-
Publication number: 20150190407Abstract: Methods of treating a subject after ocular surgery are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least one corticosteroid or an ophthalmically acceptable salt thereof in an ophthalmically acceptable vehicle that can provide a sustained release of the at least one corticosteroid or an ophthalmically acceptable salt thereof. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.Type: ApplicationFiled: January 7, 2014Publication date: July 9, 2015Applicant: INSITE VISION INCORPORATEDInventors: Kamran HOSSEINI, Lyle M. BOWMAN
-
Patent number: 9044508Abstract: Provided is concentrated aqueous azithromycin formulation from about from about 2%-20%, and a method of making a concentrated aqueous azithromycin formulation which includes preparing and sterilizing a first solution comprising a strong base to form a sterilized solution, dissolving the azithromycin in an aqueous solution comprising an acid consisting essentially of a strong acid, and adding the aqueous solution comprising the strong acid to the sterilized solution comprising the strong base. The strong acid has a pKa less than about ?1.74 and the method is carried out without addition or use of a weak acid.Type: GrantFiled: March 15, 2013Date of Patent: June 2, 2015Assignee: INSITE VISION CORPORATIONInventors: Lyle M. Bowman, Sui Yen Eddie Hou, Tang Nguyen
-
Publication number: 20140274924Abstract: Provided is concentrated aqueous azithromycin formulation from about from about 2%-20%, and a method of making a concentrated aqueous azithromycin formulation which includes preparing and sterilizing a first solution comprising a strong base to form a sterilized solution, dissolving the azithromycin in an aqueous solution comprising an acid consisting essentially of a strong acid, and adding the aqueous solution comprising the strong acid to the sterilized solution comprising the strong base. The strong acid has a pKa less than about ?1.74 and the method is carried out without addition or use of a weak acid.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: INSITE VISION INCORPORATEDInventors: Lyle M. Bowman, Sui Yen Eddie Hou, Tang Nguyen
-
Publication number: 20140142055Abstract: A method of treating a recurring meibomian gland disorder in a patient includes administering to a patient suffering from recurring meibomian gland disorder a composition comprising a therapeutically effective amount of an azalide antibiotic and a glucocorticoid. The method may thereby reduce the frequency of recurrence of the meibomian gland disorder.Type: ApplicationFiled: June 29, 2012Publication date: May 22, 2014Applicant: INSITE VISION CORPORATIONInventors: Kamran Hosseini, Lyle M. Bowman
-
Publication number: 20130177599Abstract: Provided are method and kits useful for extending the wear-time of a contact lens. The method includes applying an amount of an ophthalmically acceptable solution to the contact lens to improve the comfort of the eye when the contact lens is in the eye. The solution includes an aqueous suspension and chitosan. The aqueous suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. Upon contact with tear fluid, the solution gels to a second viscosity which is greater than the first viscosity. The kit includes contact lenses, an ophthalmically acceptable solution and instructions for applying the solution to improve the comfort of the eye when the contact lens is in the eye.Type: ApplicationFiled: January 6, 2012Publication date: July 11, 2013Inventors: Lyle M. BOWMAN, Kamran Hosseini
-
Publication number: 20130165419Abstract: Compositions and systems for topical ophthalmic application, which include an aqueous mixture of steroidal and non-steroidal anti-inflammatory agents in a flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.Type: ApplicationFiled: December 21, 2011Publication date: June 27, 2013Inventors: Richard L. Lindstrom, Kamran Hosseini, Lyle M. Bowman
-
Publication number: 20100227928Abstract: The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.Type: ApplicationFiled: March 5, 2009Publication date: September 9, 2010Inventors: Kamran HOSSEINI, Lyle M. BOWMAN, Erwin C. SI, Stephen Pham
-
Patent number: 7758553Abstract: A drop dispenser has a substantially conical sleeve member with a narrow upper end and a wide lower end. Centrally located at the apex of the upper end of the sleeve member is an aperture which has an inner diameter and is circumscribed by a raised ridge. The aperture and the ridge form a nozzle. The interior space of the substantially conical sleeve member forms a substantially conical chamber between the narrow upper end and wide lower end of the sleeve member. The nozzle is in liquid communication with the chamber through the aperture. The drop dispenser may have external threads at the lower end of the sleeve member for engaging a cap having a protuberance centrally located at its internal top end for hermetically engaging the aperture of the nozzle when the cap fully engages the sleeve member.Type: GrantFiled: April 3, 2006Date of Patent: July 20, 2010Assignees: Insight Vision Incorporated, R.P. Scherer Technologies, Inc.Inventors: Patrick Poisson, Lyle M. Bowman
-
Patent number: 7749970Abstract: The topical application of an azalide antibiotic such as azithromycin to the eye is useful in treating or preventing ocular infections. In one embodiment, the azalide antibiotic is supplied to the eye in a depot for sustained release. A more convenient dosing regimen can also be provided by the use of an appropriate depot. Furthermore, a composition containing a combination of medicaments is also provided.Type: GrantFiled: April 7, 2003Date of Patent: July 6, 2010Assignee: Insite Vision IncorporatedInventors: Chandler R. Dawson, Lyle M. Bowman
-
Patent number: 7732415Abstract: The topical application of an azalide antibiotic such as azithromycin to the eye is useful in treating or preventing ocular infections. In one embodiment, the azalide antibiotic is supplied to the eye in a depot for sustained release. A more convenient dosing regimen can also be provided by the use of an appropriate depot. Furthermore, a composition containing a combination of medicaments is also provided.Type: GrantFiled: July 26, 2004Date of Patent: June 8, 2010Assignee: Insite Vision IncorporatedInventors: Chandler R. Dawson, Lyle M. Bowman